Cite
HARVARD Citation
Banerjee, S. et al. (n.d.). 2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial. International journal of gynecological cancer. p. A410. [Online].